Neurocrine Biosciences, Inc. NBIX

NAS: NBIX | ISIN: US64125C1099   13/05/2025
116,87 USD (-2,96%)
(-2,96%)   13/05/2025
Grafiek Neurocrine Biosciences, Inc. Grafiek Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. in het nieuws

8 mei 2025 · Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups · Persbericht

6 mei 2025 · Neurocrine Biosciences to Present at Upcoming Investor Conferences in May · Persbericht

6 mei 2025 · Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia · Persbericht

5 mei 2025 · Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance · Persbericht

5 mei 2025 · Neurocrine Biosciences Announces New Survey Revealing Need for Routine Screening and Earlier Diagnosis for People Living with Tardive Dyskinesia · Persbericht

30 april 2025 · Neurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia · Persbericht

24 april 2025 · Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry · Persbericht

14 april 2025 · Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results · Persbericht

4 april 2025 · Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer · Persbericht

31 maart 2025 · Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia · Persbericht

Profiel Neurocrine Biosciences, Inc.

Biotechnologie
Gezondheidstechnologie
Productie
Productie van biologische producten

Website: www.neurocrine.com

Hoofdzetel: San Diego, California vlag Verenigde Staten

CEO: Kevin Gorman

Werknemers: 1.252

Mijn selecties